Nosocomial and community acquired uropathogenic isolates of Proteus mirabilis and antimicrobial susceptibility profiles at a university hospital in Sub-Saharan Africa

Asian Pacific Journal of Tropical Disease

Volumn 2, Issue 1, 2012, Pages 7-11

  Jombo, GTA ^a   Emanghe, U E ^b   Amefule, E N ^b   Damen, J G ^c  

^a BENUE STATE UNIVERSITY   (Nigeria)

^b UNIVERSITY OF CALABAR   (Nigeria)

^c UNIVERSITY OF JOS   (Nigeria)

Author keywords

Antimicrobial susceptibility patterns; Comunity aquired; Nosocomial; Proteus mirabilis; Sub Saharan Africa; Urinary tract infections

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLOXACILLIN; COLISTIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; NALIDIXIC ACID; NITROFURANTOIN; OFLOXACIN; STREPTOMYCIN; TETRACYCLINE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHILD; COMMUNICABLE DISEASE; FEMALE; HOSPITAL INFECTION; HUMAN; INFANT; MALE; NIGERIA; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEUS MIRABILIS; SCHOOL CHILD; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION; URINE CULTURE;

EID: 84856888100     PISSN: 22221808     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2222-1808(12)60003-6     Document Type: Article

References (51)

1. Sohn KM, Kang CJ, Joo EJ, Hu YE, Chung DR, Peck KR, et al. Epidemiology of ciprofoxaci resistance and its relationship to extended-spectrum beta-lactamase production in Proteus mirabilis bacteremia. Korean J Intern Med 2011, 26(1):89-93.
2. Okimoto N, Hayashi T, Ishiga M, Nanba F, Kishimoto M, Yagi S, et al. Clinical features of Proteus mirabilis pneumonia. J Infect Chemother 2010, 16(5):364-366.
3. Tonkic M, Mohar B, Sisko-Kraljević K, Mesko-Meglic K, Goić-Barisić I, Novak A, et al. High prevalence and molecular characterization of extended-spectrum β-lactamase-producing Proteus mirabilis strains in southern Croatia. J Med Microbiol 2010, 59(Pt 10):1185-1190.
4. Meyer WO, Pavlin JA, Hospenthal D, Murray CK, Jerke K, Hawksworth A, et al. Antimicrobial resistance surveillance in the AFHSC-GEIS network. BMC Public Health 2011, 11(Suppl 2):eS8.
5. Broeren MCC, Bahçeci S, Vader HL, Arents NLA Screening for urinary tract infection with the Sysmex UF-1000i urine flow cytometer. J Clin Microbiol 2011, 49(3):1025-1029.
6. Song W, Kim J, Kwon Bae K, Jeong SH, Seo YH, Shin JH, et al. Chromosome-encoded AmpC and CTX-M extended-spectrum β-lactamases in clinical isolates of Proteus mirabilis. Korea Antimicrob Agents Chemother 2011, 55(4):1414-1419.
7. Garcia EC, Brumbaugh AR, Mobley HLT Redundancy and specificity of Escherichia coli Iron Acquisition systems during urinary tract infection. Infect Immun 2011, 79(3):1225-1235.
8. Yin X, Hou T, Liu Y, Chen J, Yao Z, Ma C, et al. Association of toll-like receptor 4 gene polymorphism and expression with urinary tract infection types in adults. PLoS One 2010, 5(12):e14223.
9. Tijet N, Andres P, Chung C, Lucero C, WHONET-Argentina Group, Low DE, et al. rmtD2, a New Allele of a 16S rRNA Methylase Gene, Has Been Present in Enterobacteriaceae Isolates from Argentina for More than a Decade. Antimicrob Agents Chemother 2011, 55(2):904-909.
10. Harada S, Ishii Y, Saga T, Tateda K, Yamaguchi K Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate. Antimicrob Agents Chemother 2010, 54(9):3545-3550.
11. Joly-Guillou ML, Kempf M, Cavallo JD, Chomarat M, Dubreui L, Maugein J, et al. Comparative in vitro activity of meropenem, imipenem and piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. BMC Infect Dis 2010, 10:e72.
12. Spahiu L, Hasbahta V Most frequent causes of urinary tract infections in children. Medicinski Arhiv 2010, 64(2):88-90.
13. Jones CH, Tuckman M, Keney D, Ruzin A, Bradford PA Characterization of sequence analysis of extended-spectrum-β-lactamase-encoding genes from Escherichia coli, Klebsiella pneumonia and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. Antimicrob Agents Chemother 2009, 53(2):465-475.
14. Luzzaro F, Brigante G, D'Adrea MM, Pini B, Giani T, Mantengoli E, et al. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Int J Antimicrob Agents 2009, 33(4):320-323.
15. Kwiecinska-Pirog J, Boguet T, Gospodarek E The incidence of extended spectrum beta-lactamases in Proteus mirabilis strains isolated in 2007-2009. Przegl Epidemiol 2010, 64(3):395-398.
16. Papazafiropoulou A, Danill I, Sotiropoulos A, Balampani E, Kokolaki A, Bousboulas S, et al. Prevalence of asymptomatic bacteriuria in type 2 diabetic subjects with and without microalbuminuria. CMC Res Notes 2010, 3:e109.
17. Oli AN, Okafor CI, Ibezim EC, Akujobi CN, Onwunzo MC The prevalence and bacteriology of asymptomatic bacteriuria among ante-natal patients in Nnamdi Azikiwe university teaching hospital Nnewi, southeastern Nigeria. Niger J Clin Practi 2010, 13(4):409-412.
18. Martins F, Vitorino J, Abreau A Evaluation of antimicrobial susceptibility profile of micro-organisms isolated from urine in the region of Vale do Sousa and Tamega. Acta Med Port 2010, 23(4):641-646.
19. Cohen-Nahum K, Saidel-Odes L, Reisenberg K, Schaeffer F, Borer A Urinary tract infections caused by multi-drug resistant Proteus mirabilis: risk factors and clinical outcomes. Infection 2010, 38(1):41-46.
20. Canales BK, Anderson L, Higgins L, Frethem C, Ressler A, Kim IW, et al. Proteomic analysis of a matrix stone: a case report. Urological Research 2009, 37(6):323-329.
21. Sato S, Yokota C, Toyoda K, Naganuwa M, Minematsu K Hyperammonemic encephalopathy caused by urinary tract infection with urinary retention. Eur J Intern Med 2008, 19(8):e78-79.
22. Nucleo E, Fugazza G, Migliavacca R, Spalla M, Comelli M, Pagani L, et al. Differences in biofilm formation and aggregative adherence between β-lactam susceptible and β-lactamases producing P. mirabilis clinical isolates. New Microbiol 2010, 33:37-45.
23. Noreddin AM, Elkhatib WF, Cunnion KM, Zhanel GG Cumulative clinical experience from over a decade of use levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy. Drug Healthc Patient Saf 2011, 3:59-68.
24. Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol 2011, 5:1369-1379.
25. Tabibian JH, Gornbein J, Heidari A, Dien SL, Lau VH, Chahal P, et al. Uropathogens and host characteristics. J Clin Microbiol 2008, 46(12):3980-3986.
26. Custovic A, Zulcic-Nakic V, Asceric M, Hadzic S Surveillance of intrahospital infections at the clinic for gynaecology and obstetrics. Bosnian J Basic Medical Sci 2009, 9(1):66-70.
27. Sardelic S, Bedenic B, Sijak D, Colinon C, Kalenic S Emergence of Proteus mirabilis isolates producing TEM-52 extended-spectrum beta-lactamases in Croatia. Chemotherapy 2010, 56(3):208-213.
28. Falcone M, Perilli M, Mezzatesta ML, Mancini C, Amicosante G, Stefanis S, et al. Prolonged bacteraemia caused by VIM-1 metallo-beta-lactamae-producing Proteus mirabilis: First report from Italy. Clin Microbiol Infect 2010, 16(2):179-181.
29. Aiassa V, Barnes AI, Albesa I Resistance to ciprofloxacin by enhancement of antioxidant defences in biofilm and planktonic Proteus mirabilis. Biochem Biophys Res Cmmun 2010, 393(1):84-88.
30. Cohen-Nathum K, Saidel-Odes L, Reienberg K, Schlaeffer F, Borer A Urinary tract infections caused bymulti-drug resistan Proteus mirabilis: risk factors and clinical outcomes. Infection 2010, 38(1):41-46.
31. Kanayama A, Iyoda T, Matsuzaki K, Saika T, Ikeda F, Ishii Y, et al. Rapidly spreading CTX-M-type-beta-lactamase-producing Proteus mirabilis in Japan. Int J Antimicrob Agents 2010, 36(4):340-342.
32. Jombo GTA, Emanghe UE, Amefule EN, Damen JG Urinary tract infections at a Nigerian university hospital: Causes, patterns and antimicrobial susceptibility profile. J Microbiol Antimicrob 2011, 3(6):153-159.
33. Jombo GTA, Akpan S, Epoke J, Denen-Akaa P, Eyong KI, Gyuse AN Antimicrobial susceptibility profiles of community-acquired and nosocomial isolates of Escherichia coli from clinical blood culture specimens at a Nigerian University teaching hospital. Asian Pac J Tropical Med 2010, 3(8):662-665.
34. Adeleke SI, Gadanya MA An appraisal of current management of childhood urinary tract infections among private medical practitioners. Niger J Med 2009, 18(1):43-46.
35. Kelesidis T, Karageorgopoulos DE, Kelesidis L, Falagas ME Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systemic review of evidence from microbiological and clinical studies. J Antimicrob Chemother 2008, 62(5):896-904.
36. Khawcharoenpom T, Vasoo S, Ward E, Singh K High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med 2012, 30(1):68-74.
37. De Oliveira KRP, de Freitas ALP, Wiliers DMC, Barth AL, Zavaski AP High frequency of β-lactam susceptibility in CTX-m-type extended-spectrum-β-lactamase-producing Klebsiella pneumonia, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations. J Antimicrob Chemother 2010, 65:2481-2483.
38. Dediec-Ljubovic A, Hukic M Catheter-related urinary tract infections in patients suffering from spinal cord injuries. Bosn J Basic Med Sci 2009, 9(1):2-9.
39. Piljic D, Ahmetagic S, Piljic D, Zildzic M, Porobic M Aetiological factors of community-acquired urinary tract infections in hospitalized patients. Med Arh 2009, 63(3):128-132.
40. Tseng MH, Lo WT, Lin WJ, Teng CS, Chu ML, Wang CC Changing trend in antimicrobial resistance of paediatric uropathogens in Taiwan. Pediatr Int 2008, 50(6):797-800.
41. Kwiecinska-Pirog J, Bogiel T, Gospodarek K The incidence of extended-spectrum beta-lactamases in Proteus mirabilis strains isolated in 2007-2009. Przegl Epidemiol 2010, 64(3):395-398.
42. Cohen-Nahum K, Saidel-Odes L, Riesenberg K, Schlaeffer F, Borer A Urinary tract infections caused by multidrug-resistant Proteus mirabilis. Risk factors and clinical outcomes. Infection 2010, 33(1):37-45.
43. Nucleo E, Fugazza G, Migliavacca R, Spaila M, Comelli M, Pagani L, et al. Differences in biofilm formation and aggregation adherence between beta-lactam susceptible and beta-lactamases producing Proteus mirabilis clinical isolates. The New Microbiol 2010, 33(1):37-45.
44. Raffi HS, Bates JM, laszic Z, Kumar S Tamm-horsfall protein protects against urinary tract infections by Proteus mirabilis. J Urol 2009, 181(5):2332-2338.
45. Skerk V, Skerk V, Jaksic J, Lakos AK, Matrapazovski M, Malekovic G, et al. Research of urinary tract infections in family medicine physician's offices: empiric antimicrobial therapy of urinary tract infections-Croatian experience. Collegium Antropologicum 2009, 33(2):625-631.
46. Miragliotta G, Di'Pierro MN, Miragliotta L, Mosca A Antimicrobial resistance among uropathogens responsible for community-acquired urinary tract infections in an Italian community. J Chemother 2008, 20(6):721-727.
47. Lu CT, Chuang YC, Sun W, Liu YC, Cheng YJ, Lu PL, et al. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Antimicrobial Agents 2008, 32(Suppl 3):S179-S183.
48. Wu Y, Cai X Distribution and antibiotic resistance of pathogens isolated from mid-stream urine of 658 patients. Zhang Nan Da Xue Bao Yi Xue Bam 2010, 35(11):1189-1196.
49. Tralelas A, Losifidis E, Loannidou M, Saoulidis S, Kollios K, Antachopoulos C, et al. Outcome of urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in children. Paediatr Infecti Dis J 2011, PMID 21248655 [Epub ahead of print].
50. Wang M, Guo O, Xu X, Wang X, Ye X, Wu S, et al. New plasmid-mediated quinolone-resistance gene, qnrC found in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother 2009, 53(5):1892-1897.
51. Luzzaro F, Brigante G, D'Andrea MM, Pini B, Giani T, Mantengoli E, et al. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Int J Antimicrob Agents 2009, 33(4):328-333.